NCT02471222
Completed
Phase 2
Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Adamas Pharmaceuticals, Inc.
- Enrollment
- 60
- Primary Endpoint
- Safety of ADS-5102 assessed by adverse events, safety-related study drug discontinuations, vital signs, and safety laboratory test
Overview
Brief Summary
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the treatment of walking impairment in MS. ADS-5102 is designed to be administered once daily at bed time, ADS-5102 achieves higher plasma amantadine concentrations in the early morning, sustained throughout the afternoon, and lower concentrations in the evening when patients are sleeping. ADS-5102 is designed to deliver its primary treatment effect during the day, and potentially reduce the adverse events of immediate-release amantadine when the patient is asleep.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed a current IRB-approved informed consent form;
- •Male or female subjects between 18 and 70 years of age, inclusive;
- •Confirmed diagnosis of Multiple Sclerosis according to the 2010 Revised McDonald criteria;
- •On a stable regimen of medications taken specifically to treat MS for at least 30 days prior to screening, and willing to continue the same doses and regimens for the duration of study participation;
- •Stable physical activity level for at least 30 days prior to screening and willing to continue without change for the duration of study participation;
- •Maximum EDSS score during screening of 6.5;
- •Sufficient ambulatory ability to complete two trials of the Timed 25 Foot Walk (T25FW) at the screening visit;
- •A score on each completed screening T25FW test between 8 and 45 seconds, inclusive;
- •Any other current and allowed prescription/non-prescription medications and/or nutritional supplements taken regularly must have been at a stable dose and regimen for at least 30 days prior to screening, and subject must be willing to continue the same doses and regimens during study participation;
- •If taking an antidepressant, must be on a stable dose for at least 60 days prior to screening.
Exclusion Criteria
- •History of seizures within 2 years prior to screening;
- •Clinically significant MS relapse with onset less than 30 days prior to screening;
- •Presence of vertigo or other vestibular dysfunction that might compromise ability to safely perform the T25FW;
- •Received physical therapy within 30 days prior to screening;
- •Received systemic steroids within 30 days prior to screening;
- •Received dalfampridine, methylphenidate, modafinil, armodafinil, amantadine, and/or any product containing amphetamines, or any treatment specifically for fatigue or to improve walking within 30 days prior to screening;
- •Received any botulinum toxin containing product used as antispasmodic agent within 3 months prior to screening;
- •History of clinically significant hallucinations due to an MS medication or other/unknown cause, within 2 years prior to screening;
- •History of Bipolar Disorder or Psychosis, regardless of treatment;
- •Presence of cognitive impairment sufficient, in the opinion of the investigator, to affect the subject's ability to complete study assessments, or which would not be in the subject's best interest to participate in the study;
Arms & Interventions
ADS-5102 (amantadine HCl extended release)
Experimental
Intervention: ADS-5102 (Drug)
Placebo
Placebo Comparator
Intervention: Placebo (Other)
Outcomes
Primary Outcomes
Safety of ADS-5102 assessed by adverse events, safety-related study drug discontinuations, vital signs, and safety laboratory test
Time Frame: Up to 4 weeks
Secondary Outcomes
- Timed 25 Foot Walk(Up to 4 weeks)
- Timed Up and go(Up to 4 weeks)
- 2 Minute Walk Test(Up to 4 weeks)
- MS Walking Scale-12(Up to 4 weeks)
Investigators
Similar Trials
Completed
Phase 3
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)DyskinesiaLevodopa Induced Dyskinesia (LID)Parkinson's DiseaseNCT02136914Adamas Pharmaceuticals, Inc.126
Completed
Phase 3
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaDyskinesiaLevodopa-Induced Dyskinesia (LID)Parkinson's Disease (PD)NCT02274766Adamas Pharmaceuticals, Inc.77
Completed
Phase 3
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentWalking ImpairmentMultiple SclerosisNCT03436199Adamas Pharmaceuticals, Inc.558
Completed
Phase 3
Open-Label Safety Study of ADS-5102 in PD Patients With LIDDyskinesiaLevodopa Induced Dyskinesia (LID)Parkinson's Disease (PD)NCT02202551Adamas Pharmaceuticals, Inc.223
Active, not recruiting
Phase 1
A clinical trial to see if ADS-5102 is safe and effective in people with drug induced abnormal movements in Parkinson's diseaseTreatment of levodopa-induced dyskinesia in subjects with Parkinson's diseaseMedDRA version: 18.0Level: PTClassification code 10013916Term: DyskinesiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2014-003738-24-DEAdamas Pharmaceuticals, Inc.72